This prospectus supplement relates to the issuance and sale of up to $15,000,000 of shares of our common stock that we may sell to Lincoln Park Capital Fund, LLC, or Lincoln Park, from time to time pursuant to the purchase agreement, dated August 13, 2020, or the Purchase Agreement, that we have entered into with Lincoln Park, and an additional 121,584 shares of our common stock being issued to Lincoln Park as commitment shares under the Purchase Agreement. See “Lincoln Park Transaction” for a description of the Purchase Agreement and additional information regarding Lincoln Park. Lincoln Park is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act.
On August 7, 2020, Aclaris Therapeutics reported that the first patient had been dosed with ATI-450 in the company's investigator-initiated Phase 2a COVID-19 clinical trials.
The trial is a Phase 2a, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of ATI-450, when used in addition to standard of care therapy.
The primary endpoint is the proportion of subjects who are free from respiratory failure by day 14.
One important feature of ATI-450 that sets it apart from most COVID-19 therapies being tested,is that it is available orally. The vast majority of current COVID-19 therapy programs under investigation that are only available intravenously.
Aclaris is funded to 1Q 2022 not including ongoing efforts to find partners for legacy products/programs. The company enjoys strong institutional support (82%), and 4 analysts have a Buy rating with an average $4.5/share on ACRS stock.
KU researchers pivot from cancer and cystic fibrosis to test new drug for COVID-19
August 14, 2020
If this trial shows Gan and Polineni that ATI-450 can be effective at stopping the progression of COVID-19 and keeping people from needing mechanical ventilation, the investigators will be discussing next steps with Aclaris regarding the clinical development of this drug as a potential treatment for inpatients with COVID-19.
The researchers also plan to use what they learn from the trial to inform their other, separate research projects on cancer and CF
Dr. Gan had wanted to study the new investigational drug, ATI-450, developed by Aclaris Therapeutics, Inc., that he had wanted to study for its potential to slow metastasis in cancer. Now, he and Dr. Polineni are studying whether it can be used, in conjunction with standard-of-care therapy, to halt respiratory failure in patients hospitalized with COVID-19. If successful, this drug could potentially keep those patients from needing mechanical ventilation.
in letzter Zeit. Nach 50%- jetzt 70%+ in meinem Depot. Aber bis wohin kanns gehen? Bin gerade etwas ratlos, was ich tun soll. Mitnehmen oder Laufenlassen? Newsflow war ja top in letzter Zeit und die Pipeline bietet einiges an Potential. Chart sieht jetzt auch top aus. Andererseits besteht nach dem Anstieg natürlich auch jederzeit die Gefahr einer KE. HMMM, echt schwierig im Moment. Aber ich freue mich natürlich über den Anstieg. :)